Polymorphism in cytochrome P4502A6 reduces the risk to head and neck cancer and modifies the treatment outcome
- 16 October 2021
- journal article
- research article
- Published by Wiley in Environmental and Molecular Mutagenesis
- Vol. 62 (9), 502-511
- https://doi.org/10.1002/em.22466
Abstract
The present case-control study consisting of 1300 cases of head and neck squamous cell carcinoma (HNSCC) and the equal number of controls aimed to investigate the association of functionally important polymorphisms in cytochrome P4502A6 (CYP2A6*1B, CYP2A6*4C, CYP2A6*9-rs28399433) with HNSCC and the treatment response in cases receiving a combination of chemo-/radiotherapy. A significant decrease in risk to HNSCC was observed in the cases with deletion (CYP2A6*4B and CYP2A6*4C) or reduced activity genotypes (CYP2A6*9) of CYP2A6. This risk to HNSCC was further reduced significantly in tobacco users among the cases when compared to non-tobacco users among the cases. The risk was also reduced to a slightly greater extent in alcohol users among the cases when compared to non-alcohol users among the cases. In contrast with decreased risk to HNSCC, almost half of the cases with variant genotypes of CYP2A6 (CYP2A6*1A/*4C+*1B/*4C+*4C/*4C and *9/*9) did not respond to the treatment. Likewise, the survival rate in cases receiving the treatment, after 55 months of follow-up was significantly lower in cases with deletion (6.3%) or reduced activity (11.9%) allele than in the cases with common alleles (41%). The present study has shown that CYP2A6 polymorphism significantly reduces the risk to HNSCC. Our data further suggested that CYP2A6 polymorphism may worsen the treatment outcome in the cases receiving chemo-/radiotherapy.Keywords
This publication has 44 references indexed in Scilit:
- Polymorphisms in the Human Cytochrome P450 and ArylamineN-Acetyltransferase: Susceptibility to Head and Neck CancersBioMed Research International, 2013
- CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patientsBritish Journal of Cancer, 2011
- Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancerMutation research. Reviews in mutation research, 2008
- Genetic polymorphisms of glutathione-S-transferase genes (GSTM1, GSTT1 and GSTP1) and upper aerodigestive tract cancer risk among smokers, tobacco chewers and alcoholics in an Indian populationEuropean Journal of Cancer, 2007
- Identification of Novel CYP2A6*1B Variants: The CYP2A6*1B Allele is Associated With Faster In Vivo Nicotine MetabolismClinical Pharmacology & Therapeutics, 2007
- Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapyMolecular Psychiatry, 2006
- Genetic Polymorphism of CYP2A6 and Tobacco-Related Cancer Risk: From the Establishment of Genetically Engineered Salmonella to Large Scale EpidemiologyGenes and Environment, 2006
- Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-butanone (NNK) metabolism by cytochrome P450 2B6Drug Metabolism and Disposition, 2005
- An in Vivo Pilot Study Characterizing the New CYP2A6*7, *8, and *10 AllelesBiochemical and Biophysical Research Communications, 2002
- Polymorphisms of CYP2A6 and its practical consequencesBritish Journal of Clinical Pharmacology, 2001